Advanced Enzyme Tech logo

Advanced Enzyme Tech

ADVENZYMES NSE
₹259.75 0.90 (0.35%)
Market Cap
₹2,887 Cr
P/E
17.53

Advanced Enzyme Tech (ADVENZYMES) share price was ₹259.75 at the 28 Oct 2026 close; market capitalisation ₹2,887 Cr; P/E (TTM) 17.53; sector Healthcare. The share price fell 15.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 2.1% year on year to ₹189.8 Cr and net profit fell 4.5% year on year to ₹38.6 Cr (compared with Jun 2025). Promoters held 43.56% of Advanced Enzyme Tech in Sep 2026, up 0.32 percentage points from Jun 2026. Its Tapetide Score is 58/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹259.75 −48.55 −15.75% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹2,887 Cr
P/E (TTM)
17.53
EBITDA
₹264 Cr
Return on Equity
10.31%
Debt to Equity
0.02
Book Value
₹145.72
EPS (TTM)
₹14.82
52W High
₹419.00
52W Low
₹246.80

Price-based figures as of 28 Oct 2026, 15:53 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Biotechnology

Anthem Biosciences
₹832.1581.1946,894 Cr15.410.24%19.45%26.78%2,161 Cr576 Cr
Advanced Enzyme Tech (this company)
₹259.7517.532,887 Cr1.782.05%10.31%13.58%800 Cr172 Cr
CCME Global
₹31.93—144 Cr3.610.00%-0.35%0.87%0 Cr-1 Cr
Shree Ganesh Biotech
₹0.44—18 Cr0.270.00%0.59%0.81%7 Cr-0 Cr
Genomic Valley Biotech
₹43.631,454.3313 Cr3.400.00%9.13%11.32%0 Cr0 Cr
Median 5 companies₹43.6381.19144 Cr3.400.00%9.13%11.32%7 Cr0 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
58 Good
Overall score
Data confidence 100/100

Category scores

Quality Strong 67
Returns, margins, earnings quality 22%
Valuation Strong 79
Cheap vs sector & own history 24%
Growth Weak 43
Sales & profit trajectory 9%
Financial Health Strong 86
Solvency, leverage, coverage 9%
Momentum Poor 17
Trend strength, vol-adjusted 12%
Ownership Weak 37
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.9%

Weaknesses

2
  • The company has delivered a poor sales growth of 8.24% over past five years.
  • Company has a low return on equity of 10.3% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

BearishNeutralBullish

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0
Analyst Rating
Based on 1 analysts
BUY SHARE100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

Updated 28 Oct 2026

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

Revenue Growth
16.51% higher than 3Y

change over 1 year

Net Income Growth
29.55% higher than 3Y

change over 1 year

Cash Flow Change
10.02%

change over 1 year

EBITDA Margin Change
-0.41%

change over 1 year Operating margin 27% · Jun 2026

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹59.0 Cr −7.8% vs Jun 26
Reported High Mean Low

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
147
158
161
158
155
146
169
167
186
185
172
203
190
Expenses
103
107
107
102
103
104
114
122
129
124
123
140
139
Operating Profit
44
51
54
55
51
42
55
46
56
60
49
63
51
OPM %
30%
32%
33%
35%
33%
29%
33%
27%
30%
33%
29%
31%
27%
Other Income
7
6
14
-6
7
10
8
9
9
10
20
7
13
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation
9
9
9
9
9
9
9
10
10
10
10
10
10
PBT
41
48
59
40
49
42
53
43
55
60
58
60
54
Tax %
29%
27%
28%
25%
28%
21%
27%
38%
26%
25%
26%
24%
28%
Net Profit
29
35
42
30
35
33
39
27
40
45
43
45
39
EPS (₹)
2.58
3.08
3.74
2.53
3.05
2.94
3.37
2.37
3.57
3.87
3.8
3.84
3.31
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
222
293
329
391
420
444
502
529
541
624
637
746
750
Expenses
131
155
177
226
236
241
269
327
382
418
441
515
526
Operating Profit
91
138
152
165
184
203
232
203
158
206
196
230
224
OPM %
41%
47%
46%
42%
44%
46%
46%
38%
29%
33%
31%
31%
30%
Other Income
1
-3
3
1
5
6
9
6
21
21
33
46
50
Interest
9
8
4
9
5
4
3
3
3
4
5
4
2
Depreciation
9
9
13
18
21
26
28
35
35
35
37
40
40
PBT
74
118
137
139
162
179
210
171
140
188
187
233
231
Tax %
31%
35%
32%
33%
28%
26%
28%
28%
26%
27%
28%
25%
—
Net Profit
51
77
93
94
116
133
151
124
104
137
134
174
172
EPS (₹)
4.6
6.97
8.2
8.07
9.95
11.58
13.09
10.7
9.45
11.92
11.72
15.07
14.82
Div. Payout %
4%
3%
5%
6%
6%
5%
7%
9%
11%
43%
44%
36%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
22
22
22
22
22
22
22
22
22
22
22
22
Reserves
188
256
442
537
657
817
948
1,066
1,213
1,302
1,398
1,610
Borrowings
115
101
54
67
35
28
23
35
34
47
39
32
Other Liabilities
92
71
65
102
91
104
153
137
142
150
151
170
Total Liabilities
417
450
583
727
805
971
1,146
1,260
1,411
1,521
1,611
1,834
Fixed Assets
287
285
421
491
495
563
601
619
649
650
679
692
CWIP
5
7
8
11
10
10
10
15
22
41
22
51
Investments
0
0
0
0
111
124
121
102
360
403
480
584
Other Assets
125
158
153
226
188
275
413
524
380
427
430
507
Total Assets
417
450
583
727
805
971
1,146
1,260
1,411
1,521
1,611
1,834
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
54
93
107
116
129
141
163
122
140
141
142
157
Investing
-15
-10
-60
-60
-124
-43
-27
2
-286
-65
-89
-72
Financing
-36
-63
-65
-2
-43
-39
-26
-48
-26
-59
-73
-70
Net Cash Flow
2
21
-18
54
-38
60
109
75
-171
17
-20
15
Free Cash Flow
42
88
97
105
116
90
143
95
102
94
108
105
CFO/EBITDA
88
88
105
97
70
94
94
87
112
93
103
96
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
52
55
55
51
61
63
61
68
58
66
71
Inventory Days
403
358
352
339
363
361
346
402
343
375
378
335
Days Payable
89
68
57
78
46
43
56
60
67
40
47
76
Cash Conversion Cycle
374
342
351
315
369
379
353
404
344
393
397
331
Working Capital Days
-43
3
76
47
72
90
94
116
109
102
112
116
ROCE %
25%
36%
31%
25%
24%
22%
22%
16%
12%
15%
13%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Advanced Enzyme Tech insights

65 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs1.89%Promot.43.56%Others9.25%Public18.65%FIIs26.65%As ofSep 2026

Documents

Frequently Asked Questions about Advanced Enzyme Tech

What does Advanced Enzyme Technologies Ltd do?
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
Where is Advanced Enzyme Technologies Ltd (ADVENZYMES) listed?
Advanced Enzyme Technologies Ltd trades as ADVENZYMES on the NSE and under code 540025 on the BSE.
Which sector does Advanced Enzyme Technologies Ltd belong to?
Advanced Enzyme Technologies Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has a market capitalisation of ₹2,887 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd trades at a PE ratio of 17.53 as of 28 Oct 2026, on earnings per share of ₹14.82, against a book value of ₹145.72 per share.
What is the 52-week high and low of Advanced Enzyme Technologies Ltd?
Over the last 52 weeks Advanced Enzyme Technologies Ltd has traded between ₹246.8 and ₹419 as of 28 Oct 2026.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd has a dividend yield of 2.05%.
What is the Return on Equity (ROE) of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd reported a return on equity of 10.31%. Its debt-to-equity ratio is 0.02.

Company Information

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

Website advancedenzymes.com
CEO Mr. Beni Prasad Rauka CA
Employees 338
Listed 2016-08-01
Face Value ₹ 2
Shares Outstanding 11,11,51,122

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ADVENZYMES.md for Advanced Enzyme Technologies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month